Elite Pharmaceuticals Inc.
- ELTP · OTC
- Pharmaceutical Preparations
- Northvale, NJ
- 65 employees
- CIK 0001053369
Updated from SEC filings through
Top things to know
Revenue, FY2026$149M+77.1% vs FY2025Operating margin33.0%Operating income $49.1MEmployees65As of June 25, 2026Next earningsNovember 14, 2026AnnouncedLatest 8-KDeparture or appointment of directors or officers; compensationFiled November 3, 2026Leadership changeItem 5.02 filedNovember 3, 2026, last 90 days
Executives
- Nasrat Hakim President, Chief Executive Officer and Chairman of the Board of Directors 10-K, 2026-06-29
- Carter Ward Chief Financial Officer 10-K, 2026-06-29
- Douglas Plassche Executive Vice President of Operations 10-K, 2026-06-29
- Kirko Kirkov Chief Commercial Officer 10-K, 2026-06-29
Elite Pharmaceuticals Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Northvale, NJ. It trades as ELTP on OTC. Revenue was $149M in the fiscal year ending March 31, 2026, +77.1% from the year before. It reported about 65 employees. Nasrat Hakim is President, Chief Executive Officer and Chairman of the Board of Directors.
Five-year financials
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | $149M 10-K, 2026-06-29 | $84.0M 10-K, 2026-06-29 | $56.6M 10-K, 2025-06-30 | $34.2M 10-K, 2024-07-01 | $32.3M 10-K, 2023-06-29 |
| Operating income | $49.1M 10-K, 2026-06-29 | $19.6M 10-K, 2026-06-29 | $10.8M 10-K, 2025-06-30 | $3.7M 10-K, 2024-07-01 | $5.1M 10-K, 2023-06-29 |
| SG&A | $17.6M 10-K, 2026-06-29 | $9.0M 10-K, 2026-06-29 | $7.1M 10-K, 2025-06-30 | $5.1M 10-K, 2024-07-01 | $4.5M 10-K, 2023-06-29 |
| Net income | $44.9M 10-K, 2026-06-29 | -$4.3M 10-K, 2026-06-29 | $20.1M 10-K, 2025-06-30 | $3.6M 10-K, 2024-07-01 | $8.9M 10-K, 2023-06-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Nasrat Hakim | President, Chief Executive Officer and Chairman of the Board of Directors | 10-K, 2026-06-29 |
| Carter Ward Chief Financial Officer at Elite Pharmaceuticals, Inc. | Chief Financial Officer | 10-K, 2026-06-29 |
| Douglas Plassche | Executive Vice President of Operations | 10-K, 2026-06-29 |
| Kirko Kirkov | Chief Commercial Officer | 10-K, 2026-06-29 |
| Barry Dash | Director | 10-K, 2026-06-29 |
| Davis Caskey | Director | 10-K, 2026-06-29 |
| Jeffrey Whitnell | Director | 10-K, 2026-06-29 |
What Elite Pharmaceuticals Inc does
, a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.
Shares and governance
| Shares outstanding | 1.08 billion (as of August 13, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $534M (as of September 30, 2025) | 10-K, June 29, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting June 23, 2020 (filed April 29, 2020) | DEF 14A, April 29, 2020 |
| Auditor | Forvis Mazars, LLP (Iselin, NJ) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 9, 2026 | Barry H. Dash Director | Buy | 100,000 | $26K | Form 4, October 19, 2026 |
| August 19, 2026 | Barry H. Dash Director | Buy | 30,000 | $9K | Form 4, September 10, 2026 |
| October 2, 2025 | Douglas Plassche EVP Operations | Sale | 800,000 | $496K | Form 4, October 3, 2025 |
| August 22, 2025 | Pharmaceuticals Inc /Nv/ Elite EVP Operations | Sale | 500,000 | $260K | Form 4, August 26, 2025 |
| July 10, 2025 | Kirko Kirkov Chief Commercial Officer | Buy | 16,366 | $10K | Form 4, July 25, 2025 |
| July 8, 2025 | Douglas Plassche EVP Operations | Sale | 200,000 | $116K | Form 4, July 10, 2025 |
Recent 8-K events
- 8-K filed 2026-11-03
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-10
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-04
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-29
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-23
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-15
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-01
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-04-02
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-02-17
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Elite Pharmaceuticals Inc
- What does Elite Pharmaceuticals Inc do?
- In its own words, from Item 1 of its 10-K: ", a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada."
- What is Elite Pharmaceuticals Inc's revenue?
- $149M for the fiscal year ending March 31, 2026, from its 10-K filed June 29, 2026.
- Is Elite Pharmaceuticals Inc profitable?
- Elite Pharmaceuticals Inc reported net income of $44.9M for the fiscal year ending March 31, 2026.
- How many employees does Elite Pharmaceuticals Inc have?
- About 65 as of June 25, 2026, as stated in its annual report.
- Who is the CEO of Elite Pharmaceuticals Inc?
- Nasrat Hakim, President, Chief Executive Officer and Chairman of the Board of Directors, as named in a 10-K filed June 29, 2026.
- Who is the CFO of Elite Pharmaceuticals Inc?
- Carter Ward, Chief Financial Officer, as named in a 10-K filed June 29, 2026.
- Where is Elite Pharmaceuticals Inc headquartered?
- Northvale, NJ.
- What is Elite Pharmaceuticals Inc's stock ticker?
- ELTP on OTC.
- What industry is Elite Pharmaceuticals Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Elite Pharmaceuticals Inc's website?
- elitepharma.com.
- When does Elite Pharmaceuticals Inc report earnings next?
- November 14, 2026. Source: estimate_10q_cadence.
- Is Elite Pharmaceuticals Inc a public company?
- Yes. Elite Pharmaceuticals Inc files with the SEC under CIK 0001053369 and trades as ELTP.
- Who audits Elite Pharmaceuticals Inc?
- Forvis Mazars, LLP, Iselin, NJ, as named in its latest annual report (10-K).
- How many shares of Elite Pharmaceuticals Inc are outstanding?
- 1.08 billion shares as of August 13, 2026, from its 10-Q filed August 13, 2026.
- What is Elite Pharmaceuticals Inc's public float?
- $534M as of September 30, 2025, as reported on the cover of its 10-K filed June 29, 2026.
- How many business segments does Elite Pharmaceuticals Inc report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is Elite Pharmaceuticals Inc's annual shareholder meeting?
- June 23, 2020, per its proxy statement (DEF 14A) filed April 29, 2020.
- Have Elite Pharmaceuticals Inc insiders traded stock recently?
- Since July 8, 2025, officers and directors reported 3 open-market sales worth about $872K and 3 purchases worth about $44K on Forms 4 and 5. The most recent: Barry H. Dash (Director) bought 100,000 shares on October 9, 2026.